scholarly journals The Characteristics Comparison of Breast Cancer Patients in Southern China and America: A Multicentre Study in China Versus SEER Database

2020 ◽  
Author(s):  
Yingjie Niu ◽  
Fan Zhang ◽  
Dong Chen ◽  
Guolin Ye ◽  
Yong Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Tumor Size ◽  
Southern China ◽  
The United States ◽  
Morbidity And Mortality ◽  
Lymph Node Status ◽  
Seer Database ◽  
Breast Cancer Patients ◽  
Ki 67

Abstract Background and Objective: The morbidity and mortality of breast cancer are increasing in recent years, which had become the second main cause of cancer death in women. However, there are different characteristics of breast cancer in developing countries and developed countries. What’s more, it has not reported the comparison of breast cancer between southern China and the United States. We intend to compare the age, different stages and grades of tumor and treatment methods, in order to study the factors which influence the survival and prognosis of breast cancer patients. Methods: To study the two groups which have been diagnosed with breast cancer in southern China from 2001 to 2016 and SEER database from 1975 to 2016. To register, collect and analyze the clinicopathological features and treatment information. To follow up the patients who have been diagnosed before 2016. Kaplan-Meier method was used to evaluate disease-free survival (DFS) and overall survival (OS). Results: Young breast cancer patients accounted for 19.8% and 6.14% respectively in southern China and SEER cohort. The early diagnostic rate of breast cancer is high in southern China, but still lower than SEER cohort. Our study found that there are significant differences in tumor size and positive lymph node status between southern China and SEER cohort (P=0.000), which notably affect the OS of breast cancer patients (P=0.018 and P=0.000). Furthermore, KI-67 is also an important prognostic factor of breast cancer patients in southern China, which also affect the OS of patients (P=0.034). In treatment, there are also significant differences between the two regions. In southern China, there are 4.91% of breast cancer patients performed breast conserving surgery and 95.09% patients performed mastectomy. But in SEER cohort, there are only 4.91% patients preformed breast surgery. Conclusions: The age, tumor size, positive-node and KI-67 may cause the difference of morbidity and mortality of breast cancer patients in southern China and SEER cohort. Overall, the prognosis of breast cancer patients in SEER cohort is better than southern China.

scholarly journals The Comparison of Breast Cancer in Southern China and America: a Multicentre Study in China Versus SEER Database

2021 ◽  
Author(s):  
Yingjie Niu ◽  
Fan Zhang ◽  
Dong Chen ◽  
Guolin Ye ◽  
Yong Li ◽  
...  
Keyword(s):  
Tumor Size ◽  
Southern China ◽  
Developed Countries ◽  
The United States ◽  
Positive Lymph Node ◽  
Lymph Node Status ◽  
Seer Database ◽  
Ki 67 ◽  
Treatment Information ◽  
The Difference

Abstract Background and Objective: There are different characteristics of BC in developing countries and developed countries. We intend to study the factors which influence the survival and prognosis of BC between southern China and the United States. Methods: To study the two groups BC patients in southern China from 2001 to 2016 and SEER database from 1975 to 2016. To register, collect and analyze the clinicopathological features and treatment information. Results: Our study found that there are significant differences in tumor size, positive lymph node status and KI-67 between southern China and SEER cohort (P<0.000). Conclusions: The age, tumor size, positive-node and KI-67 may cause the difference of morbidity and mortality of BC patients in southern China and SEER cohort.

scholarly journals The Comparison of Breast Cancer in Southern China and America: A Multicentre Study in China Versus SEER Database

2021 ◽  
Author(s):  
Yingjie Niu ◽  
Fan Zhang ◽  
Dong Chen ◽  
Guolin Ye ◽  
Yong Li ◽  
...  
Keyword(s):  
Tumor Size ◽  
Southern China ◽  
Developed Countries ◽  
The United States ◽  
Positive Lymph Node ◽  
Lymph Node Status ◽  
Seer Database ◽  
Ki 67 ◽  
Treatment Information ◽  
The Difference

Abstract Background and Objective: There are different characteristics of BC in developing countries and developed countries. We intend to study the factors which influence the survival and prognosis of BC between southern China and the United States. Methods: To study the two groups BC patients in southern China from 2001 to 2016 and SEER database from 1975 to 2016. To register, collect and analyze the clinicopathological features and treatment information. Results: Our study found that there are significant differences in tumor size, positive lymph node status and KI-67 between southern China and SEER cohort (P<0.000). Conclusions: The age, tumor size, positive-node and KI-67 may cause the difference of morbidity and mortality of BC patients in southern China and SEER cohort.

Breast cancer in "young" women: Age cutoff and clinicopathologic features.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e12019-e12019
Author(s):  
Gang Nie ◽  
Haibo Wang ◽  
Yuhua Song ◽  
Yan Mao ◽  
Weihong Cao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Family History ◽  
Cancer Patients ◽  
Older Patients ◽  
Age Groups ◽  
Her2 Status ◽  
Lymph Node Status ◽  
Breast Cancer Patients ◽  
Ki 67

e12019 Background: Age of patients play a key role in outcome of breast cancer, and therefore influences choice of treatment. In most studies, "young" is defined as being below 40 or 35 years. However, there are conflicts concerning definition of younger and older patients. In this study, we aim to establish a more appropriate age cut-off between “younger” and “older” breast cancer patients. Methods: A total of 5984 female breast cancer patients recruited in the Breast Cancer Registry of the Affiliated Hospital of Qingdao University during 2008 to 2014 were enrolled. Patients were divided into 11 groups by every 5 years’ age difference. The clinical characteristics and overall survival (OS) were compared among these age groups. Results: Among the five groups under age 45 (n = 1771, 30.0%), larger proportion of patients underwent breast conservation surgery in the “30-34” group (p = .027), and more patients were found with family history in the “25-29” group than in other groups (p = .029). No significant difference was found in OS (p = .059), clinicopathological stage, lymph node status, ER/PR status, HER2 status, or Ki-67 status among those five groups. For patients above 45 (n = 4813, 70.0%), differences were found in OS (p = .001) and significant differences with clinicopathological features (lymph node status, ER/PR status, HER2 status and Ki-67 status) were shown between younger and the older age groups (p = .001) among the six groups, except for family history (p = .066). Conclusions: Clinicopathological characteristics and survival status are similar among breast cancer patients under 45 years and vitiate among older patients. Age 45 is an appropriate cut-off for clinical grouping of breast cancer patients by age .

Frequency and predictors of insufficient chemotherapy use among stage I-III breast cancer patients by molecular subtype.

2015 ◽  
Vol 33 (28_suppl) ◽  
pp. 154-154
Author(s):  
Lu Zhang ◽  
Tekeda Freeman Ferguson ◽  
Xiao-cheng Wu ◽  
Mei-Chin Hsieh ◽  
Elizabeth Fontham ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Tumor Size ◽  
Older Age ◽  
Stage I ◽  
Lymph Node Status ◽  
Breast Cancer Patients ◽  
High Poverty ◽  
Luminal A

154 Background: Identification of distinct molecular subtypes has expanded the treatment options for breast cancer, however, chemotherapy remains the common and effective treatment for each subtype. The objective is to compare the frequency and predictors of insufficient chemotherapy use among two subtypes of stage I-III breast cancer patients: luminal A and triple negative breast cancer (TNBC). Methods: We analyzed data from a CDC funded project - Enhancing Cancer Registry Data for Comparative Effectiveness Research (CER) collected by Louisiana Tumor Registry. Women aged < = 70 years, diagnosed in 2011 with stage I-III luminal A or TNBC breast cancer, tumor size > 1cm, were included (N = 1,189). Insufficient chemotherapy (i.e. no chemotherapy use, nonstandard regimen use, and low relative dose intensity (RDI < 85%)) was evaluated respectively. Potential predictors included age, race, insurance, marital status, census tract-poverty, AJCC stage, grade, tumor size, lymph node status, and Charlson comorbidity. Stepwise model selection with p-value for entry at 0.2 and for stay at 0.25 was used to select the most relevant predictors. Results: The frequencies of no chemotherapy use were significantly different (p < .0001) between luminal A (42%, N = 913) and TNBC patients (9%, N = 241). Older age, white race, no insurance, lower stage or grade, and without lymph node involvement were related with no chemotherapy for luminal A patients; older age, not married, and high poverty for TNBC. There were 36% of luminal A and 40% of TNBC patients receiving nonstandard regimen (p = 0.27). Predictors of nonstandard regimen use were increased age, insurance, stage, and grade for luminal A and high poverty level and stage for TNBC. Reduced RDI occurred in 9% luminal A and 10% TNBC patients (p = 0.61). Small cases precluded the prediction model for low RDI. Conclusions: Luminal A patients are less likely to receive chemotherapy than TNBC patients. Low social economic status factors are associated with no chemotherapy use and nonstandard regimens use, especially for TNBC patients.

scholarly journals Changes of breast cancer staging when AJCC prognostic staging manual is used: a retrospective analysis of a Chinese cohort

2017 ◽  
Vol 33 (2) ◽  
pp. 168-173 ◽  
Author(s):  
Jinhua Ding ◽  
Weizhu Wu ◽  
Jianjiang Fang ◽  
Yudong Chu ◽  
Siming Zheng ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Tumor Size ◽  
Medical Center ◽  
Univariate Analysis ◽  
Lymph Node Status ◽  
Axillary Lymph ◽  
Breast Cancer Patients ◽  
Ajcc Staging

Background: This study aimed to investigate staging changes for Chinese breast cancer patients assessed by the 7th (anatomic) and 8th (prognostic) editions of the AJCC staging manual, and to explore the predictive factors for these changes. Methods: Data of patients who received curative surgery for stage I-III breast cancer at Ningbo Medical Center Lihuili Eastern Hospital were retrospectively reviewed. The assessment of staging was according to the criteria of the 7th and 8th editions of the AJCC staging manual. Univariate and multivariate logistic regression analyses were performed to analyze the associations between staging changes and clinicopathological characteristics. Results: Staging changes were found in 59.37% of patients and were more likely to be seen in stage IIIA (96.10%) and IIA (85.94%), then IIB (70.33%), IB (68.75%), followed by IA (36.17%) and IIIC (30.08%). In univariate analysis, staging changes were associated with tumor location, clinical tumor size, clinical axillary lymph node status and Ki67 index. However, multivariate analysis found that staging changes were significantly associated with tumor size >2 cm (odds ratio [OR] = 3.263, 95% confidence interval [95% CI], 2.638-4.036), lymph node involvement (OR = 2.261, 95% CI, 1.830-2.794) and high Ki-67 index (OR = 1.661, 95% CI 1.343-2.054). Conclusions: Our study demonstrated that there were marked staging changes when 2 different editions of the AJCC staging manual were used. Since prognostic biomarkers are available in routine clinical practice, the more recent staging manual should be followed to select better systemic therapy and give better outcomes for Chinese breast cancer patients.

scholarly journals Ki-67 Labeling Index in Primary Invasive Breast Cancer from Sudanese Patients: A Pilot Study

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Khalid Dafaallah Awadelkarim ◽  
Renato Mariani-Costantini ◽  
Ihsan Osman ◽  
Massimo Costanzo Barberis
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Tumor Size ◽  
Interquartile Range ◽  
Labeling Index ◽  
Breast Cancer Patients ◽  
Ki 67 ◽  
Significant Group ◽  
Cancer Subtypes ◽  
Her 2

Ki-67 labeling index has been linked to patient outcome in breast cancer patients. However, very few published reports have examined Ki-67 labeling index in African breast cancer patients. Sixty-two Sudanese breast cancer patients with primary invasive tumors were immunostained for Ki-67, ER, PR, Her-2/neu, CK5/6, and CK17. Ki-67 labeling index ranged from 0% to 50%, with a median of 5% (interquartile range 0–10). Low Ki-67 labeling index (immunostaining < 10%) was detected in 43/62 (69.4%) with a median of 0 (interquartile range 0–5), whereas high Ki-67 labeling index (immunostaining ≥ 10%) was revealed in 19/62 (30.6%) with a median of 20 (interquartile range 12–26). Ki-67 labeling index was significantly associated with tumor grade (P=0.022, Mann-Whitney U Test). There were no significant group differences between Ki-67 labeling index and ER (P=0.43), PR (P=0.7), Her-2/neu (P=0.45), CK5/6 (P=0.29), CK17 (P=0.55), pathologic stage (P=0.4), tumor histology (P=0.99), breast cancer subtypes (P=0.47), tumor size (P=0.16), and age at diagnosis (P=0.6). These results suggested that Ki-67 labeling index correlates with tumor differentiation and not with the tumor size or any other tested marker in Sudanese breast cancers. Thus, Ki-67 labeling index could be considered as a reliable measure of tumor proliferative fraction in Sudan.

Explanation model using pathological data for treatment outcome of patients with early-stage breast cancer with hormonal receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e12006-e12006
Author(s):  
Naiyarat Prasongsook
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Adjuvant Treatment ◽  
Hormonal Therapy ◽  
Tumor Size ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Breast Cancer Patients ◽  
Ki 67

e12006 Background: The decision to initiate adjuvant chemotherapy for early-stage breast cancer patients with HR+ and HER2- is still unclear. Although the 21-gene Recurrence Score (RS) assay is a validated testing and becomes an emerging decision-making tool; it is still controversial guidance on adding adjuvant chemotherapy for patients with intermediate RS. This study aimed to develop the explanation model by using pathological information for prediction of the best outcome from adjuvant systemic treatment in these patients.Methods: Early-stage breast cancer patients with HR+, and HER2- who underwent complete resection registered within electronic medical record from 2003 to 2013 were included. Patient’s characteristics and pathological information were collected and analyzed. Univariate and multivariate analysis were conducted by using stepwise logistic regression. The explanation model was explored by using association between multivariate models and overall survival (OS).Results: 236 patients who underwent complete surgery treatment were included. 121 patients (51%) were treated with sequential adjuvant treatment, and 115 patients (48%) with anti-hormonal therapy alone. Clinicopathological parameters between two groups were demonstrated in Table1. Tumor size (≥2 – 5 cm), Estrogen receptor-negative/ Progesterone receptor-positive (ER-/PgR+), and Ki-67 expression were statistically significant multivariate independent prognostic factors for OS. When we adjusted for tumor size, HR status, and Ki-67 expression, the explanation model predicted 10-year OS was 99.2% for patients with sequential adjuvant treatment, whereas 89.5% for patients with adjuvant anti-hormonal alone (difference: 9.7%); p-value = 0.01.Conclusions: We found substantial discordance in 10-year OS benefit between early-breast cancer patients with HR+, HER2- with sequential adjuvant therapy and adjuvant hormonal therapy alone. Adjuvant chemotherapy should be considered in early-breast cancer patients with 2-3 cm in tumor size, ER-/PgR+, and Ki 67 expression.

Sign in / Sign up

Export Citation Format

Share Document